Clinical trial
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With…
NCT00431990 · Peter MacCallum Cancer Centre, Australia, Other · Unknown status
Key facts
| NCT number | NCT00431990 |
|---|---|
| Title | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma |
| Official title | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma |
| Lead sponsor | Peter MacCallum Cancer Centre, Australia, Other |
| Collaborators | Celgene Corporation Industry Janssen-Cilag Ltd. |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | depsipeptide, bortezomib, dexamethasone |
| Enrollment | 40 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2011 |
| Completion | Jan 1, 2012 |
| First posted | Feb 6, 2007 |
| Last update posted | Aug 12, 2011 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: